Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro

Authors: You-feng Guo, Xiao-bing Wang, Xiao-ying Tian, Yang Li, Bin Li, Quan Huang, Meng Zhang, Zhi Li

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

We examined the association of tumor-derived hepatocyte growth factor (HGF) with the clinicopathological features of gliomas and investigated the effect of HGF inhibition on the biological behavior of tumor cells in vitro in order to determine whether HGF is a valuable prognostic predictor for glioma patients.

Methods

Seventy-six cases of glioma were collected. The tumor-derived HGF expression, cell proliferation index (PI) and intratumoral microvessels were evaluated by immunohistochemistry. Correlation between immunostaining and clinicopathological parameters, as well as the follow-up data of patients, was analyzed statistically. U87MG glioma cells were transfected with short interference (si)-RNA for HGF, and the cell viability, migratory ability and chemosensitivity to cisplatin were evaluated in vitro.

Results

Both high HGF expression in tumor cells (59.2%, 45/76) and high PI were significantly associated with high-grade glioma and increased microvessels in tumors (P < 0.05). However, only histological grading (P = 0.004) and high-expression of HGF (P = 0.008) emerged as independent prognostic factors for the overall survival of glioma patients. The tumor-derived HGF mRNA and protein expressions were significantly decreased in vitro after transfection of HGF siRNA. HGF siRNA inhibited the cell growth and reduced cell migratory ability. Moreover, HGF siRNA transfection enhanced the chemosensitivity of U87MG glioma cells to cisplatin.

Conclusion

This study indicated that there was significant correlation among tumor cell-derived HGF, cell proliferation and microvessel proliferation in gliomas. HGF might influence tumor progression by modulating the cell growth, migration and chemoresistance to drugs. Increased expression of HGF may be a valuable predictor for prognostic evaluation of glioma patients.
Appendix
Available only for authorised users
Literature
1.
Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol. 2005, 109: 93-108. 10.1007/s00401-005-0991-y.CrossRefPubMed
2.
Ohgaki H: Epidemiology of brain tumors. Methods Mol Biol. 2009, 472: 323-342. 10.1007/978-1-60327-492-0_14.CrossRefPubMed
3.
Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y, Chiriboga L, Lukyanov E, Liu M, Newcomb EW: Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer’s structures. Am J Pathol. 2008, 173: 545-560. 10.2353/ajpath.2008.071197.PubMedCentralCrossRefPubMed
4.
Giese A, Bjerkvig R, Berens ME, Westphal M: Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003, 21: 1624-1636. 10.1200/JCO.2003.05.063.CrossRefPubMed
5.
Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA: Prognostic factors for anaplastic astrocytomas. J Neurooncol. 2007, 81: 295-303. 10.1007/s11060-006-9232-z.CrossRefPubMed
6.
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21: 2683-2710. 10.1101/gad.1596707.CrossRefPubMed
7.
Boros P, Miller CM: Hepatocyte growth factor: A multifunctional cytokine. Lancet. 1995, 345: 293-295. 10.1016/S0140-6736(95)90279-1.CrossRefPubMed
8.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003, 4: 915-925. 10.1038/nrm1261.CrossRefPubMed
9.
Osada S, Kanematsu M, Imai H, Goshima S: Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology. 2008, 55: 544-549.PubMed
10.
Xie LQ, Bian LJ, Li Z, Li Y, Li ZX, Li B: Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol. 2010, 17: 1927-1936. 10.1245/s10434-010-0922-6.CrossRefPubMed
11.
Lamszus K, Schmidt NO, Jin L, Laterra J, Zagzag D, Way D, Witte M, Weinand M, Goldberg ID, Westphal M, Rosen EM: Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer. 1998, 75: 19-28. 10.1002/(SICI)1097-0215(19980105)75:1<19::AID-IJC4>3.0.CO;2-4.CrossRefPubMed
12.
Laterra J, Rosen E, Nam M, Ranganathan S, Fielding K, Johnston P: Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Biochem Biophys Res Commun. 1997, 235: 743-747. 10.1006/bbrc.1997.6853.CrossRefPubMed
13.
Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J: In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002, 16: 108-110.PubMed
14.
Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J: Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol. 2010, 97: 347-351. 10.1007/s11060-009-0037-8.CrossRefPubMed
15.
Abounader R, Montgomery R, Dietz H, Laterra J: Design and expression of chimeric U1/ribozyme transgenes. Methods Mol Biol. 2004, 252: 209-219.PubMed
16.
Hecht M, Papoutsi M, Tran HD, Wilting J, Schweigerer L: Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res. 2004, 64: 6109-6118. 10.1158/0008-5472.CAN-04-1014.CrossRefPubMed
17.
Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997, 57: 5391-5398.PubMed
18.
Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, Laterra J: Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res. 2000, 60: 4277-4283.PubMed
19.
Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009, 27: 5743-5750. 10.1200/JCO.2009.23.0805.CrossRefPubMed
20.
Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME: MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol. 2010, 6: 39-51. 10.1038/nrneurol.2009.197.CrossRefPubMed
21.
Lou X, Zhou Q, Yin Y, Zhou C, Shen Y: Inhibition of the met receptor tyrosine kinase signaling enhances the chemosensitivity of glioma cell lines to CDDP through activation of p38 MAPK pathway. Mol Cancer Ther. 2009, 8: 1126-1136. 10.1158/1535-7163.MCT-08-0904.CrossRefPubMed
22.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO classification of tumors of the central nervous system. 2007, IARC Press, Lyon
23.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330.CrossRefPubMed
24.
Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999, 17: 2762-2771.PubMed
25.
Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg. 1992, 76: 741-745. 10.3171/jns.1992.76.5.0741.CrossRefPubMed
26.
Xie LQ, Bian LJ, Li Z, Li Y, Liang YJ: Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma. Oncol Rep. 2010, 23: 141-150.CrossRefPubMed
27.
Rubio L, Burgos JS, Morera C, Vera-Sempere FJ: Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients. Pathol Oncol Res. 2000, 6: 210-216. 10.1007/BF03032375.CrossRefPubMed
28.
Lamszus K, Laterra J, Westphal M, Rosen EM: Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. 1999, 17: 517-530. 10.1016/S0736-5748(99)00008-8.CrossRefPubMed
29.
Li Z, Bian LJ, Li Y, Liang YJ, Liang HZ: Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis. Pathol Res Pract. 2009, 205: 542-550. 10.1016/j.prp.2009.01.015.CrossRefPubMed
30.
Li-juan B, Bing L, Zhi L, Yang L, Ying-jie L: Hepatocyte growth factor suppresses tumor cell apoptosis in nasopharyngeal carcinoma by upregulating Bcl-2 protein expression. Pathol Res Pract. 2009, 205: 828-837. 10.1016/j.prp.2009.06.016.CrossRefPubMed
31.
Abounader R, Laterra J: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005, 7: 436-451. 10.1215/S1152851705000050.PubMedCentralCrossRefPubMed
32.
Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H, Tominaga T: Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res. 1998, 4: 659-664.PubMed
33.
Niki M, Isozaki H, Toyoda M, Ishibashi T, Fujii K, Nomura E, Mabuchi H, Nakamura M, Nishiguchi K, Tanigawa N: Serum human hepatocyte growth factor (hHGF) is elevated in patients with metastatic gastric carcinoma. Hepatogastroenterology. 1998, 45: 2458-2463.PubMed
34.
Brockmann MA, Ulbricht U, Grüner K, Fillbrandt R, Westphal M, Lamszus K: Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery. 2003, 52: 1391-1399. 10.1227/01.NEU.0000064806.87785.AB.CrossRefPubMed
35.
Moriyama T, Kataoka H, Kawano H, Yokogami K, Nakano S, Goya T, Uchino H, Koono M, Wakisaka S: Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett. 1998, 124: 149-155. 10.1016/S0304-3835(97)00469-2.CrossRefPubMed
36.
Moskowitz SI, Jin T, Prayson RA: Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol. 2006, 76: 193-200. 10.1007/s11060-005-5262-1.CrossRefPubMed
37.
Hoshino T, Ahn D, Prados MD, Lamborn K, Wilson CB: Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J Cancer. 1993, 53: 550-555. 10.1002/ijc.2910530404.CrossRefPubMed
38.
Prados MD, Krouwer HG, Edwards MS, Cogen PH, Davis RL, Hoshino T: Proliferative potential and outcome in pediatric astrocytic tumors. J Neurooncol. 1992, 13: 277-282.CrossRefPubMed
39.
Kunkel P, Müller S, Schirmacher P, Stavrou D, Fillbrandt R, Westphal M, Lamszus K: Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro Oncol. 2001, 3: 82-88.PubMedCentralPubMed
40.
Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ: AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2005, 10: 975-987. 10.2741/1592.CrossRefPubMed
41.
Fan M, Chambers TC: Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat. 2001, 4: 253-267. 10.1054/drup.2001.0214.CrossRefPubMed
42.
Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M: Gruppo Italiano Cooperativo di Neuro-Oncologia: First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol. 2004, 22: 1598-1604. 10.1200/JCO.2004.11.019.CrossRefPubMed
43.
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, Riva D, Ruggiero A, Valentini L, Mazza E, Genitori L, Di Rocco C, Navarria P, Casanova M, Ferrari A, Luksch R, Terenziani M, Balestrini MR, Colosimo C, Fossati-Bellani F: High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002, 20: 4209-4216. 10.1200/JCO.2002.08.087.CrossRefPubMed
44.
Sheleg SV, Korotkevich EA, Zhavrid EA, Muravskaya GV, Smeyanovich AF, Shanko YG, Yurkshtovich TL, Bychkovsky PB, Belyaev SA: Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol. 2002, 60: 53-59. 10.1023/A:1020288015457.CrossRefPubMed
Metadata
Title
Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro
Authors
You-feng Guo
Xiao-bing Wang
Xiao-ying Tian
Yang Li
Bin Li
Quan Huang
Meng Zhang
Zhi Li
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-128

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue

Case report

Using polypropylene mesh graft for soft-tissue reconstruction in internal hemipelvectomy: a case report

Research

Clinical predictors of right upper paraesophageal lymph node metastasis from papillary thyroid carcinoma

Research

Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer

Research

Prognostic criteria in patients with gastrointestinal stromal tumors: a single center experience retrospective analysis

Research

Low accuracy of endoscopic ultrasonography for detailed T staging in gastric cancer

Research

Long term survival results for gastric GIST: is laparoscopic surgery for large gastric GIST feasible?